Edition:
India

Bio-Path Holdings Provides Clinical Update And 2019 Business Outlook


Thursday, 27 Dec 2018 

Dec 27 (Reuters) - Bio Path Holdings Inc ::BIO-PATH HOLDINGS PROVIDES CLINICAL UPDATE AND 2019 BUSINESS OUTLOOK.BIO PATH HOLDINGS - EXPECTS TO INITIATE PHASE 1 CLINICAL TRIAL OF BP1002 IN REFRACTORY OR RELAPSED LYMPHOMA AND CLL PATIENTS IN 2019.BIO PATH HOLDINGS INC - IN 2019, BIO-PATH INTENDS TO INITIATE A PHASE 1 CLINICAL TRIAL OF PREXIGEBERSEN IN PATIENTS WITH ADVANCED SOLID TUMORS.